As much as I enjoyed the bounce from the article, I don't think it did us good in the long run. It read like a pump piece and he's a shareholder and not credentialed to speak about medicine. I think it was much more significant that Dr. Saphier wrote about leronlimab even though she actually got everything wrong about where we are in the trials. She's head of breast radiology at Sloane Kettering in NJ. Not a slouch. I wish more prominent doctors and science journalists would write about it.